Trial Disruptions In Uncertain Times: Q&A With 4G’s Barry Moore
By Deborah Borfitz
April 21, 2020 | Study sponsors are facing an unprecedented level of clinical supply disruptions caused by the COVID-19 pandemic. For insights on the current struggles of clinical supply study managers, innovations being deployed and ways to build a more resilient supply chain for future trials, Clinical Research News spoke with Barry Moore at randomization and trial supply management provider 4G Clinical.
Moore is 4g’s newly appointed vice president of delivery, and the previous head of clinical supply solutions at GlaxoSmithKline (GSK). While at GSK, he also served as chairman of the Clinical Supply Blockchain Working Group, developer of a blockchain-powered iPhone app for pharmaceutical clinical supply chains.
Tag(s):
News
Related Blog Posts Headline
View All Blog Posts
May 6, 2020
Society for Clinical Research Sites (SCRS): Podcast with 4G's Neta Bendelac on Direct-to-Patient Trials
Read More
December 7, 2017
4G Clinical: Natural Language Processing to Accelerate Clinical Trials
Read More
September 26, 2018